European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY), a global specialty-driven pharmaceutical group, today announced that the European Commission has approved Cabometyx™ (cabozantinib) 20, 40, 60...